Nykredit A S Buys New Position in Pfizer Inc. $PFE

Key Points

• Nykredit A/S purchased 6.38 million Pfizer shares worth approximately $153.7 million in the second quarter, giving it a 0.11% stake. Institutional investors collectively own 68.36% of Pfizer.
• Analyst sentiment remains mixed but centers on a “Hold” consensus, with a consensus price target of $28.39; ratings include one Strong Buy, four Buys, fourteen Holds and two Sells.
• Pfizer reported quarterly EPS of $0.77 and revenue of $15.03 billion, beating estimates, while paying a quarterly dividend of $0.43 per share—an annualized yield of approximately 6.2%.

Nykredit A S purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 6,382,727 shares of the biopharmaceutical company's stock, valued at approximately $153,696,000. Nykredit A S owned 0.11% of Pfizer as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Norges Bank purchased a new position in shares of Pfizer during the 4th quarter worth approximately $1,830,986,000. Bank of America Corp DE purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $1,049,602,000. BlackRock Inc. boosted its position in shares of Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company's stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Finally, Capital World Investors grew its stake in Pfizer by 51.5% in the fourth quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company's stock worth $533,704,000 after purchasing an additional 7,287,194 shares during the period. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent research reports. Weiss Ratings raised Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 31st. UBS Group reaffirmed a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research note on Friday, August 7th. JPMorgan Chase & Co. lowered their price target on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Wednesday, July 8th. Finally, Royal Bank Of Canada raised shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $28.39.

Pfizer Trading Up 0.6%

NYSE PFE opened at $27.64 on Friday. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $29.21. The stock has a market cap of $157.52 billion, a P/E ratio of 36.36, a P/E/G ratio of 1.84 and a beta of 0.34. The stock's fifty day moving average price is $26.63 and its 200-day moving average price is $26.37. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the firm earned $0.78 EPS. Pfizer's quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. Pfizer's dividend payout ratio is presently 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.